Exicure to Pay GPCR Therapeutics $1 Million for First Milestone Completion
On January 23, US-based biotech company Exicure announced that it had successfully completed the first milestone stipulated in the license and collaboration agreement signed with GPCR Therapeutics Inc. on January 16.
According to a disclosure filed with the US Securities and Exchange Commission (SEC), this milestone was achieved by Exicure officially submitting the Clinical Study Report for a new stem cell mobilizer-considered a key drug candidate in the field of regenerative medicine-currently under development, to the US Food and Drug Administration (FDA).
In accordance with the contract terms, Exicure is scheduled to pay GPCR Therapeutics 1 million US dollars (approximately 1.4 billion KRW) within 30 days of achieving the milestone.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An Exicure representative stated, "This milestone achievement reflects the progress in the development of Burixafor (GPC-100), a small molecule drug in the CXCR4 inhibitor class. It also affects the revenue sharing ratio for subsequent sublicense (re-license) agreements and indicates an increase in Exicure's participation share in the program."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.